Vaxcyte, Inc.
NASDAQ:PCVXBiotechnology
+$1.94 today
- Market cap
- $9.26B
- Beta
- 1.24
- P/E (TTM)
- -7.8
- EPS (TTM)
- -$6.78
Volume 1.13M
Average 1.44M
PCVX Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Vaxcyte, Inc.NASDAQ: PCVX
Depreciation & Amortization · Q2 FY2026 · quarter ended Jun 2026
Depreciation & amortization grows, but more slowly than its trailing trend
Q2 FY2026 depreciation & amortization of $5.95M rose 19.2% year over year, behind the +40.0% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 1.6% from the prior quarter. Over 3 fiscal years it compounded at +38.0% a year.
Context
- Depreciation & amortization increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +19.2% toward the trailing-twelve-month pace of +40.0%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 24.86M USD
- Year-over-year change
- +56.9%
- 4-year CAGR
- +63.8%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 24.86M | +56.9% |
| FY2024 | 2024-12-31 | 15.85M | +55.8% |
| FY2023 | 2023-12-31 | 10.17M | +7.6% |
| FY2022 | 2022-12-31 | 9.45M | +173.4% |
| FY2021 | 2021-12-31 | 3.46M | — |
Depreciation & Amortization vs competitors
How PCVX compares with its peers on the latest reported figures
- Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +40.0% is the 3rd highest of 9, against a peer median of +0.8%.
- Over three fiscal years its annual growth of +38.0% compares with a peer median of +1.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $6.58B USD | -3.0% | +9.2% | 10.3% | |
| LTM Jun 2026 | £2.21B GBP | -34.0% | +2.5% | 6.7% | |
| LTM Sep 2026 | $257M USD | +23.6% | -14.8% | 10.2% | |
| LTM Jun 2026 | $26.8M USD | +40.0% | +38.0% | — | |
| LTM Mar 2026 | €25.21M EUR | +138.6% | +1.1% | 16.1% | |
| LTM Mar 2026 | $22.34M USD | -50.0% | -1.7% | 3.7% | |
| LTM Mar 2026 | $18.23M USD | +41.3% | +46.1% | 27.8% | |
| LTM Sep 2026 | $16.54M USD | +4.6% | -5.3% | 9.1% | |
| LTM Mar 2026 | $2.88M USD | -16.2% | +25.6% | 6.4% | |
| Peer median (excluding PCVX) | — | +0.8% | +1.8% | 9.6% | |
Competitors are the stored peer set for PCVX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (100.08M) | (223.49M) | (402.27M) | (463.93M) | (766.63M) |
| Depreciation & Amortization | 3.46M | 9.45M | 10.17M | 15.85M | 24.86M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 10.73M | 23.65M | 48.76M | 84.82M | 138.85M |
| Change in Working Capital | (37.01M) | 12.74M | 81.32M | (54.9M) | (3.45M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (12.47M) | 2.9M | 11.23M | 34.58M | 19.91M |
| Other Working Capital | (24.54M) | 9.84M | 70.1M | (89.48M) | (23.36M) |
| Other Non-Cash Items | 1.5M | 7.05M | (34.78M) | (34.47M) | (49.2M) |
| Operating Cash Flow | (121.39M) | (170.6M) | (296.79M) | (452.63M) | (655.58M) |
| Capital Expenditures | (6.56M) | (5.84M) | (67.88M) | (22.43M) | (13.71M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (336.34M) | (102.75M) | (1.33B) | (3.09B) | (1.21B) |
| Sales of Investments | 130.56M | 183.17M | 624.46M | 1.2B | 1.71B |
| Other Investing Activities | 26K | 0 | 0 | (96.73M) | (43.26M) |
| Investing Cash Flow | (212.31M) | 74.59M | (773.31M) | (2.01B) | 437.35M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 13.9M | 856.48M | 636.04M | 2.44B | 13.01M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 3.9M | 5.07M | 3.77M | 12.85M | (10.99M) |
| Financing Cash Flow | 17.8M | 861.55M | 639.81M | 2.45B | 2.01M |
| Effect of Forex Changes | (439K) | 137K | (6.69M) | 426K | 2.44M |
| Net Change in Cash | (316.34M) | 765.67M | (436.97M) | (9.36M) | (213.77M) |
| Free Cash Flow | (127.95M) | (176.44M) | (364.67M) | (475.05M) | (669.29M) |
Vaxcyte, Inc.
NASDAQ:PCVX
Intrinsic Alpha fair value
Locked
Current Price
$58.52
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.